

Technology Advisory Committee D Interests Register
Efgartigimod for treating generalised myasthenia gravis [ID4003]
Publication Date: 4 June 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Rachel Elliot	Committee Member	Direct – financial	Rachel received payment by CSL Behring for an advisory board this year on an unrelated topic	03/07/2023	It was agreed that Rachel's declaration would not prevent her from participating in discussions on this appraisal
Dr Ivan Koychev	Committee Member	Direct- non-financial personal interest	Dr Koychev declared that a close friend of his is Senior Medical Director at Argenx.	18/07/2023 16/11/2023 15/04/2024	It was agreed that Dr Koychev's declaration would not prevent him from participating in discussions on this appraisal
Dr Will Sullivan	Committee Member	Direct – non-financial professional	Will is an employee of a consultancy company that provides paid services to various pharmaceutical companies. He has provided consultancy work through his employment for two potential competitor companies for this appraisal in the last 12 months: <ul style="list-style-type: none"> Will is part of a team providing ongoing health economic consultancy services to 	16/04/2024 05/12/2024	It was agreed that Will's declaration would not prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Novartis concerning the technology asciminib to treat newly diagnosed chronic myelogenous leukaemia</p> <ul style="list-style-type: none"> In a previous role within the last 12 months, Will was part of a team providing consultancy services to Hoffman La-Roche concerning the technologies trastuzumab and pertuzumab to treat HER2+ breast cancer 		
Dr Channa Hewamadduma	Clinical Expert	Direct – financial	<p>Dr Hewamadduma declared the following financial interests:</p> <ul style="list-style-type: none"> UCB Pharma Received funding for consultancy on scientific or educational advisory boards. Argenx Received funding for consultancy on scientific or educational advisory boards. Lupin Received funding for consultancy on scientific or educational advisory boards. Roche Received funding for consultancy on scientific or educational advisory boards. Biogen Received funding for consultancy on scientific or educational advisory boards. Association of British Neurologists (ABN)- Chaired a symposium organised by Biogen 	<p>26/06/2023</p> <p>16/11/2023</p>	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>on SMA- new insights from basic science to understand SMA</p> <ul style="list-style-type: none"> Association of British Neurologists (ABN) – Lecture on Mechanisms of Myasthenia gravis – in an educational symposium on MG arranged by ARGEX One off Consultation for UCB 		
Dr Channa Hewamadduma	Clinical Expert	<p>Direct- nonfinancial</p> <p>Indirect - professional</p>	<p>Dr Hewamadduma declared his involvement in clinical trials in MG/CIDP: sponsors: UCB, Argenx (ongoing), Jansen (setup).</p> <p>Dr Hewamadduma also declared the following indirect interests:</p> <ul style="list-style-type: none"> Publication- author – Contributing author to Phase 3 clinical trial and manuscript. Lancet Neurology 2023 (May) 2023 March: Core teaching faculty of an Academic programme on Myasthenia Gravis at Neurology Academy- who were sponsored by ARGEX and UCB 	26/06/2023	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.
Dr Channa Hewamadduma	Clinical Expert	Direct - financial	<ul style="list-style-type: none"> Dr Hewamadduma is Principal Investigator to new trials for MG and CIDP where sponsors are Argenx, immunovant and Biogen. Dr Hewamadduma has received honoraria for speaking and adhoc advisory 	09/05/2024	It was agreed that Dr Hewamadduma's declarations would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			consultation and research support from UCB and from Argenx, Roche, and Biogen		
Dr Fiona Norwood	Clinical Expert	Direct – financial and non-financial interests	Dr Norwood declared the following interests: <ul style="list-style-type: none"> • Speaking engagement for argenx • Advisory board for argenx • Advisory board for UCB • Trustee for patient organisation Myaware • Has received honoraria from Roche 	12/12/2022 16/11/2023 09/05/2024	It was agreed that Dr Norwood's declarations would not prevent her from providing expert advice to the committee.
Emtiyaz Chowdhury	HST Committee member – volunteer	Direct – non-financial professional	Emtiyaz works for Parexel. Parexel is a CRO which works with the manufacturer. He has not been directly involved in any work related to this specific technology/indication.	26/11/2024	It was agreed that Emtiyaz's declaration would not prevent them from participating in discussions on this appraisal
Charlotte Campbell	Patient Expert	Direct – non-financial professional	Charlotte is employed by their nominating organisation, myaware, where they act as an advocate for the patients who may directly benefit from this technology.	05/12/2024	It was agreed that Charlotte's declarations would not prevent them from providing expert advice to the committee.
Dr Channa Hewamadduma	Clinical Expert	Direct - financial	Dr Hewamadduma is a trustee of Myaware since Sept 2024 and Chief Investigator in MG/CIDP clinical trials of Novartis, Immunovant, JnJ and RemGen.	05/12/2024	It was agreed that Dr Hewamadduma's declarations would not prevent him from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>Dr Hewamadduma declared the following financial interests:</p> <ul style="list-style-type: none"> Phase III CIDP study Efgartigimod vs SOC – Dr Hewamadduma is a contributing author and PI in the ADHERE study. Lancet Neurology 2024 (Argenx) Steroid Sparing effects of Zilucoplan – Dr Hewamadduma is the lead author of manuscript/ conference presentations (UCB) ongoing 2024 Advisory boards with Argenx (MMN), Avidity Sept-Nov 2024 Speaker honoraria - Argenx, UCB, Biogen, Roche Sept-Nov 2024 UK MG guideline development core group MG patient pathway and network development programme - Neurology academy. 		providing expert advice to the committee.
Ashwin Pinto	Clinical Expert	Direct - Financial	Ashwin has received honoraria and lecture fees from UCB Pharma, Argenx and Terumo BCT in the last five years.	05/12/2024	It was agreed that Ashwin's declarations would not prevent them from providing

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
					expert advice to the committee.